Work

International Psoriasis Council psoriasis disease severity reclassification: Update on validity, acceptance, and implementation

Year: 2025

Type: article

Abstract: Contains fulltext : 324605.pdf (Publisher’s version ) (Open Access)

Source: Journal of the American Academy of Dermatology

DOI: 10.1016/j.jaad.2025.05.1445

Authors: Bruce E. Strober, Andrew Blauvelt, Peter CM. van de Kerkhof, Álvaro González-Cantero, Mona El-Kalioby, Cesar Gonzalez, Benjamin Hidalgo Matlock, Filip Rob, Pravit Asawanonda, Rudi Chandra, Julia-Tatjana Maul, Tiago Torres, Lone Skov

Institutions: Yale University, Maryland Department of Agriculture, Radboud University Medical Center, Universidad Francisco de Vitoria, Hospital Universitario Ramón y Cajal, Cairo University, Universidad de Costa Rica, Hospital Nacional de Niños, Latin University of Costa Rica, Charles University, Chulalongkorn University, Universitas Prima Indonesia, University of Zurich, University Hospital Zurich, Universidade do Porto, Hospital de Santo António, University of Copenhagen, Gentofte Hospital

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,200

Funders: Bristol-Myers Squibb, National Psoriasis Foundation, Eli Lilly and Company, Pfizer, Sanofi, Biogen, Celgene, Mylan, Kongelig Hofbuntmager Aage Bangs Fond, Galderma, LEO Fondet, LEO Pharma, Samsung

OpenAlex ID: W4411089287

FWCI: 1.786

Cites: 5

Cited by: 6

Related to: 10